NEXI News

The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble (BMBL), which completed the year's largest deal so far, and Chinese cloud services provider Cloopen Group (RAAS), which bagged the biggest pop of 2021 to date. Bumble (BMBL) priced further...read more

NexImmune, a Phase 1/2 biotech developing T cell immunotherapies for cancer, raised $110 million by offering 6.5 million shares at $17, the high end of the range of $15 to $17. NexImmune originally filed to sell 4.7 million shares, before increasing the offering to 5.9 million shares on Thursday, and further upsizing the deal at pricing. Existing shareholders had intended to...read more

NexImmune, a Phase 1/2 biotech developing T cell immunotherapies for cancer, raised the proposed deal size for its upcoming IPO on Thursday. The Gaithersburg, MD-based company now plans to raise $94 million by offering 5.9 million shares at a price range of $15 to $17. The company had previously filed to offer 4.7 million shares at the same range. Existing shareholders...read more

NexImmune, a Phase 1/2 biotech developing T cell immunotherapies for cancer, announced terms for its IPO on Monday. The Gaithersburg, MD-based company plans to raise $75 million by offering 4.7 million shares at a price range of $15 to $17. Existing shareholders intend to purchase $20 million worth of shares in the offering. At the midpoint of the proposed range, NexImmune...read more